SG10201912498YA - Mutated truncated von willebrand factor - Google Patents
Mutated truncated von willebrand factorInfo
- Publication number
- SG10201912498YA SG10201912498YA SG10201912498YA SG10201912498YA SG10201912498YA SG 10201912498Y A SG10201912498Y A SG 10201912498YA SG 10201912498Y A SG10201912498Y A SG 10201912498YA SG 10201912498Y A SG10201912498Y A SG 10201912498YA SG 10201912498Y A SG10201912498Y A SG 10201912498YA
- Authority
- SG
- Singapore
- Prior art keywords
- von willebrand
- willebrand factor
- mutated truncated
- truncated von
- mutated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900034A AU2016900034A0 (en) | 2016-01-07 | Mutated truncated von willebrand factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912498YA true SG10201912498YA (en) | 2020-02-27 |
Family
ID=59273076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805497QA SG11201805497QA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
| SG10201912498YA SG10201912498YA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805497QA SG11201805497QA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10806774B2 (en) |
| EP (1) | EP3400002B1 (en) |
| JP (1) | JP6851381B6 (en) |
| KR (1) | KR20180094114A (en) |
| CN (1) | CN108472338B (en) |
| AU (1) | AU2017204955B2 (en) |
| BR (1) | BR112018013861A2 (en) |
| CA (1) | CA3010720A1 (en) |
| DK (1) | DK3400002T3 (en) |
| ES (1) | ES2909573T3 (en) |
| HK (1) | HK1256525A1 (en) |
| MX (1) | MX2018008337A (en) |
| RU (1) | RU2018128582A (en) |
| SG (2) | SG11201805497QA (en) |
| WO (1) | WO2017117631A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
| DK3538133T3 (en) * | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR THE TREATMENT OF HEMOPHILIA |
| JP2020530436A (en) | 2017-06-22 | 2020-10-22 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Regulation of FVIII immunogenicity by truncated VWF |
| MA53020A (en) * | 2018-05-18 | 2021-05-05 | Zhengzhou Gensciences Inc | ENHANCED FVIII FUSION PROTEIN AND ASSOCIATED USE |
| JP2021523878A (en) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | How to treat hemophilia A |
| US10654911B1 (en) | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
| KR20220029733A (en) * | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII |
| CN110624105B (en) * | 2019-09-24 | 2021-06-11 | 苏州大学 | Sequences of structurally sensitive polypeptide antigens of von Willebrand factor |
| JP2023500953A (en) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Polypeptides for inducing tolerance to factor VIII |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| FR2673632A1 (en) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| DE4435485C1 (en) | 1994-10-04 | 1996-03-21 | Immuno Ag | Process for obtaining high-purity von Willebrand factor |
| CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| WO1997040145A1 (en) | 1996-04-24 | 1997-10-30 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| PT1079805E (en) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| JP2005518181A (en) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| ES2331909T3 (en) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | FACTOR VIII STABILIZED WITH GENETICALLY MODIFIED DISULFIDE LINKS. |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| WO2003093313A2 (en) | 2002-04-29 | 2003-11-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| EP1575998A4 (en) | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | Mammalian cell culture processes for protein production |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CN1767857A (en) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | Polymer-factor VIII moiety conjugates |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2298347B1 (en) | 2003-05-06 | 2015-09-30 | Biogen Hemophilia Inc. | Clotting factor chimeric proteins for treatment of a hemostatic disorder |
| CN1802386B (en) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | GLP-1 analog fusion proteins |
| DK1699821T3 (en) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| WO2006053299A2 (en) | 2004-11-12 | 2006-05-18 | Bayer Healthcare Llc | Site-directed modification of fviii |
| ES2434035T3 (en) | 2004-12-27 | 2013-12-13 | Baxter International Inc. | Polymer-von Willebrand factor conjugates |
| CA2604299A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| PL3896090T3 (en) | 2006-06-14 | 2022-05-02 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| KR20100095441A (en) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | Modified recombinant factor viii and von willebrand factor and methods of use |
| KR101648734B1 (en) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
| US8748380B2 (en) | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| JP5876416B2 (en) | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Von Willebrand factor (vWF) containing preparations and related methods, kits and uses |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| EP2705051A1 (en) | 2011-05-05 | 2014-03-12 | Novozymes Biopharma DK A/S | Albumin variants |
| WO2013093760A2 (en) * | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| BR112014017165B1 (en) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF |
| EP2814502B1 (en) * | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| AU2013234299B2 (en) | 2012-03-16 | 2017-06-22 | Albumedix Ltd. | Albumin variants |
| EP2841451A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| CN110054699A (en) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | Factor IX compound with XTEN and vWF ELISA albumen, and application thereof |
| MX2015005363A (en) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Albumin variants. |
| CN105452289A (en) | 2013-06-12 | 2016-03-30 | 诺和诺德股份有限公司 | Compounds suitable for treatment of haemophilia |
| RU2714154C2 (en) | 2014-06-06 | 2020-02-12 | Октафарма Аг | Preparation containing viii factor and von willebrand factor peptides |
| DK3164150T3 (en) * | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | MODIFIED BY WILLEBRAND FACTOR |
| US10364982B2 (en) * | 2015-11-19 | 2019-07-30 | Ansaldo Energia Switzerland AG | Method for reconditioning fuel nozzle assemblies |
| SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
-
2017
- 2017-01-06 SG SG11201805497QA patent/SG11201805497QA/en unknown
- 2017-01-06 DK DK17735769.6T patent/DK3400002T3/en active
- 2017-01-06 AU AU2017204955A patent/AU2017204955B2/en active Active
- 2017-01-06 WO PCT/AU2017/050010 patent/WO2017117631A1/en active Application Filing
- 2017-01-06 MX MX2018008337A patent/MX2018008337A/en unknown
- 2017-01-06 SG SG10201912498YA patent/SG10201912498YA/en unknown
- 2017-01-06 US US16/068,181 patent/US10806774B2/en active Active
- 2017-01-06 EP EP17735769.6A patent/EP3400002B1/en active Active
- 2017-01-06 RU RU2018128582A patent/RU2018128582A/en not_active Application Discontinuation
- 2017-01-06 BR BR112018013861A patent/BR112018013861A2/en not_active Application Discontinuation
- 2017-01-06 CA CA3010720A patent/CA3010720A1/en active Pending
- 2017-01-06 JP JP2018535395A patent/JP6851381B6/en active Active
- 2017-01-06 KR KR1020187022666A patent/KR20180094114A/en active Search and Examination
- 2017-01-06 ES ES17735769T patent/ES2909573T3/en active Active
- 2017-01-06 CN CN201780005952.4A patent/CN108472338B/en active Active
-
2018
- 2018-12-05 HK HK18115593.9A patent/HK1256525A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190015483A1 (en) | 2019-01-17 |
| JP6851381B6 (en) | 2021-04-21 |
| BR112018013861A2 (en) | 2018-12-18 |
| JP6851381B2 (en) | 2021-03-31 |
| CN108472338B (en) | 2022-12-30 |
| EP3400002A1 (en) | 2018-11-14 |
| DK3400002T3 (en) | 2022-04-11 |
| EP3400002A4 (en) | 2019-07-03 |
| US10806774B2 (en) | 2020-10-20 |
| KR20180094114A (en) | 2018-08-22 |
| MX2018008337A (en) | 2018-09-17 |
| ES2909573T3 (en) | 2022-05-09 |
| AU2017204955B2 (en) | 2021-04-01 |
| EP3400002B1 (en) | 2022-02-02 |
| WO2017117631A1 (en) | 2017-07-13 |
| CA3010720A1 (en) | 2017-07-13 |
| HK1256525A1 (en) | 2019-09-27 |
| RU2018128582A (en) | 2020-02-11 |
| CN108472338A (en) | 2018-08-31 |
| AU2017204955A1 (en) | 2018-07-12 |
| SG11201805497QA (en) | 2018-07-30 |
| JP2019507587A (en) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256525A1 (en) | Mutated truncated von willebrand factor | |
| IL262482A (en) | Novel polypeptides | |
| PL3496173T3 (en) | Perovskite material | |
| SG11201703053PA (en) | Mutated immunoglobulin-binding polypeptides | |
| SG10201912857XA (en) | Mutated von willebrand factor | |
| GB201611530D0 (en) | Novel polypeptides | |
| GB201521640D0 (en) | Novel porous materials | |
| EP3164150A4 (en) | Modified von willebrand factor | |
| GB201803983D0 (en) | Materials | |
| HK1250625A1 (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| IL249294A0 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| GB201708113D0 (en) | Materials | |
| HK1250724A1 (en) | Methods for preparing modified von willebrand factor | |
| GB2561947B (en) | Tissue-adhesive materials | |
| IL253657A0 (en) | Additive-incorporated building materials | |
| HK1244292A1 (en) | Modified von willebrand factor having improved half-life | |
| SG10201912360SA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| GB201619652D0 (en) | Novel polypeptides | |
| PL3225606T3 (en) | Construction materials | |
| GB201708013D0 (en) | Materials | |
| GB201614462D0 (en) | Clotting factor | |
| SG11201706657PA (en) | Compounds for improving the half-life of von willebrand factor | |
| AU2016900034A0 (en) | Mutated truncated von willebrand factor | |
| AU2016900033A0 (en) | Mutated von willebrand factor | |
| AU2014902532A0 (en) | Modified von willebrand factor |